Motley Fool Premium
  1. Stocks
    2. /
  2. AstraZeneca PLC (LSE: AZN)
    3. /

LSE:AZN (AstraZeneca PLC)

About AZN

AstraZeneca is a biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Respiratory, Inflammation and Autoimmunity (RIA), Cardiovascular and Metabolic Disease (CVMD) and Oncology – as well as in Infection and Neuroscience.
Financial Market Data copyright © 2026 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

AstraZeneca PLC (LSE: AZN) Latest News

A young Asian woman holding up her index finger
Investing Articles

1 FTSE 100 share I’d put 100% of my money into

| Harshil Patel

Picking just one FTSE 100 stock to buy is a challenge. Our writer racks his brain to find his number…

Read more »

Smartly dressed middle-aged black gentleman working at his desk
Investing Articles

3 cheap UK shares I’d buy to help protect my portfolio in a recession

| Charlie Carman

Defensive UK shares can outperform in challenging economic conditions. Our writer explores three stocks he'd buy in a recession.

Read more »

Young Caucasian girl showing and pointing up with fingers number three against yellow background
Investing Articles

These three FTSE 100 stocks have huge upside

| Ryan Hogg

Ryan Hogg identifies a trio of FTSE 100 stocks that not only pay a dividend yield of more than 2%…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

Here’s the AstraZeneca dividend forecast for 2023

| Edward Sheldon, CFA

Here, Edward Sheldon looks at the AstraZeneca dividend forecast for this year with the pharma giant slowly increasing its dividend…

Read more »

Female Doctor In White Coat Having Meeting With Woman Patient In Office
Investing Articles

Earnings: why AstraZeneca shares are climbing

| Alan Oscroft

AstraZeneca shares have stormed ahead as the company's long-term rebuild is delivering revenue growth. Results for 2022 are here.

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

These were the FTSE 100’s biggest flops in January!

| Cliff D'Arcy

The FTSE 100 index had a good January, rising by 4.3%. While the shares of 86 Footsie firms rose last…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Page

Top UK Large-Cap Stocks of 2025

| Zaven Boyrazian, CFA

Discover the expansive world of UK large-cap stocks and learn how these can provide stability and income to an investment…

Read more »

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

Tempted by the AstraZeneca share price? Here’s why it could explode in 2023

| Charlie Carman

The AstraZeneca share price has more than doubled over five years. Our writer outlines why the FTSE 100 healthcare stock…

Read more »

Inflation in newspapers
Investing Articles

2 inflation-resistant stocks I’d like to buy right now

| Ben McPoland

These two firms are on my 'stocks to buy' list for when I have more cash to invest. Both seem…

Read more »

Investing Articles

3 ‘no-brainer’ FTSE 100 shares I’d buy for 2023

| Harshil Patel

FTSE 100 top picks! Our writer considers diversification, resilience and business quality to find the best shares for his ISA…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

Revealed! The most sold FTSE 100 stocks by Hargreaves Lansdown investors

| Royston Wild

Demand for these FTSE 100 stocks sank among Hargreaves Lansdown clients this year. But could they rebound in 2023?

Read more »

Investing Articles

Are AstraZeneca shares a growth buy for 2023?

| Roland Head

AstraZeneca's surging share price has made it the most valuable business in the FTSE 100. Roland Head analyses what's next…

Read more »